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Recognition of the tumour suppressive capacity of the Promyelocytic Leukemia protein (PML) has
emerged beyond its identiﬁcation through APL, to a broad spectrum of tumors. This ability has
chieﬂy been linked to its role as a core component of dynamic structures termed PML Nuclear
Bodies (PML-NBs). In response to a variety of stresses, key factors and their molecular modiﬁers
are recruited to PML-NBs, where activating modiﬁcations are facilitated, leading to a cellular stress
response. PML was also found to perform anti-tumourigenic functions through cytoplasmic activi-
ties. Surprisingly, important recent research deﬁned growth promoting capabilities of PML, which
signiﬁcantly challenges the notion of a ‘classic’ tumour suppressor. Through metabolic reprogram-
ming, PML can afford a selective advantage for tumor cells in certain settings. The multiple forms in
which PML exists are the likely explanation of this functional diversity. This behavioral ambiguity
however raises a signiﬁcant challenge to the design of strategies to therapeutically target PML. In
this review we discuss this change of paradigm in the PML ﬁeld and its ramiﬁcations, particularly
for tailoring cancer therapies.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The promyelocytic leukemia (PML) protein has gained the rep-
utation of a tumour suppressor, however newly disclosed proper-
ties imply that it is a multi-faceted entity, far more complex and
enigmatic than originally perceived [1–3]. PML disruption in acute
promyelocytic leukemia (APL, a distinct subtype of acute myeloid
leukemia) led to its identiﬁcation. In APL, chromosomal transloca-
tion t(15;17) in the hematopoietic compartment produces the
oncogenic fusion protein PML-RARa, which blocks the differentia-
tion of granulocyte/monocyte progenitors [4–8]. PML deregulation
driven by alternative mechanisms is also now recognized in a
broad spectrum of malignancies outside the hematopoietic context
[9–11]. The intention of this review is to provide a contemporary
survey of the contribution of PML to tumour suppression, to ex-
plore the contexts in which it adopts the capacity to support
growth, and discuss the implications of these apparently contradic-
tory functions for therapy.
In normal cells, PML is enriched in distinct subnuclear struc-
tures known as PML-nuclear bodies (PML-NBs), where it is anessential component and key organizer (Fig. 1) [12]. PML-NBs are
dynamic structures triggered by DNA damage, oxidative stress,
transformation and viral infection [13,14]. In response to cellular
stresses, the post-translational modiﬁcation of SUMOylation ap-
pears to be instrumental [15] for PML-NBs to undergo signiﬁcant
changes in number, size and position [16]. In this process, the res-
ident protein population is bolstered by transient protein recruit-
ment, and a plethora of protein partners have been identiﬁed to
localize in, or recruit to PML-NBs [17]. PML-NBs can consequently
be heterogeneous in composition, which enables functional diver-
sity. PML-NBs involvement is implicated in a wide range of cellular
functions including: transcriptional regulation, cell cycle control,
anti-viral response, DNA damage response and repair, apoptosis
and metabolism [16,18]. Critically, PML-NBs and their functions
are lost in various tumors of different histological origin [19].
2. The role of PML as a tumour suppressor
A tumor suppressive function for PML is strongly supported in
genetically engineered mouse cancer models [6,20]. Pertinently,
PML knock out mice are not prone to cancer, although their en-
hanced susceptibility to bacterial infection indicates deﬁciencies
in the innate immune response (consistent with its role in hemato-
poietic progenitor differentiation) [21]. In the context of additional
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Fig. 1. Tumor suppression functions of PML. PML displays tumor suppression functions by acting both in the cytoplasm and in the nucleus. In the cytoplasm, PML increases
TGFb signaling by facilitating the formation of a complex between TGFb receptors, SARA and Smad2/3 and promoting their translocation into the early endosomes.
Perpetration of this signal to the nucleus may induce apoptosis as the ultimate consequence. In response to stress, a fraction of cPML localized in the mitochondria-associated
membranes (MAMs) facilitates the release of calcium from the endoplasmic reticulum (ER) to the mitochondria to also promote apoptosis. In the nucleus, PML is enriched in
the PML nuclear bodies (PML-NBs), where in response to different kinds of stress it orchestrates a wide range of cellular responses involved in tumor suppression including
apoptosis, cell cycle arrest and senescence. With regard to execution of these functions, only a partial identiﬁcation of individual isoform capabilities has been deﬁned. Most
speciﬁcally: PML-6 (VI) [60,103], PML-4 (IV) [79] and PML-7 (VIIb) [39] have been implicated in apoptosis, PML-4 (IV) in cell cycle regulation [61] and PML-1 (I) [63] and PML-
4 (IV) [52] in senescence response.
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emerged. PML deﬁciency in the context of PTEN+/ mice resulted
in invasive colon adenocarcinoma [22]. Tumour burden and
aggressiveness of KrasG12D-induced non-small cell lung cancer
(NSCLC) was signiﬁcantly increased in the absence of PML [23].
Most recently, PML tumour suppressive capacity has been demon-
strated in a mouse model of B-lymphoma driven by c-myc [24] and
in the context of mutant p53 [10]. In a broad spectrum of human
tumours of different histological origins (both hematopoietic and
solid tumours), transcriptional down-regulation, or loss of PML
protein expression compared with the corresponding normal tis-
sues, is also supportive of its tumour suppressive role [10,19,24–
28]. In addition, low expression of PML correlates with a bad prog-
nosis and high-grade tumours for breast adenocarcinomas and
prostate carcinomas [19].
One of the critical anticancer functions of PML is to facilitate
stabilization of the key tumour suppressor p53 [6,29,30], allowing
it to transcriptionally activate growth suppressive targets like p21
[31,32]. This is achieved in response to stress, by PML sequestering
p53’s major inhibitor Mdm2 to the nucleolus [33] and facilitating
p53 to associate with kinases that confer vital stabilizing, post-
translational modiﬁcations: homeodomain-interacting protein ki-
nase-2 at p53 Ser46 [34], Checkpoint 2 kinase at p53 Ser20 [35]and Casein kinase 1 at p53 Thr18 [36]. Intriguingly, PML is itself
a p53 target gene that acts downstream of p53 to potentiate its
antiproliferative effects [37], implying that these two important
tumor suppressors impact on each other through a positive regula-
tory loop. Thus, under stress conditions the p53-PML network pro-
pels itself through a positive regulatory loop leading to a cytotoxic
or cytostatic response, unless the loop is interrupted by an inhibi-
tor of the loop, such as E6AP or Mdm2 [38].
Most tumor suppression activities of PML are ascribed to its
roles in the nucleus; however, in the last decade, exciting research
has identiﬁed that cytoplasmic PML (cPML; see also Section 4 be-
low) can also regulate tumour suppression. The ﬁrst evidence of
PML acting as a tumour suppressor in the cytoplasmwas published
by Lin et al., who reported that cPML is an essential modulator of
transforming growth factor b (TGFb) signaling [39] (Fig. 1). TGFb
is a pluripotent cytokine that controls key tumour suppressive
functions [40–42]. TGFb is capable of executing important cell cy-
cle regulatory functions and inducing apoptosis through either the
SMAD or DAXX pathways [41,43]. TGFb signal transduction is per-
petuated through engagement of its receptor complex at the cell
surface, internalization of the bound complex through the early
endosomes pathway, and consequent propagation of the signal to
the nucleus via activation of the Smads transcriptional factors
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receptors into early endosomes, thus facilitating Smads activation
[42,45]. Pertinently, cPML is crucial in orchestrating this signaling
event, as it is required for the TGFb receptors/SARA/Smads complex
assembly and internalization into the early endosomes (Fig. 1)
[39]. Consistently, if cPML is sequestered into the nucleus by
TGFb-induced factor homeobox 1 (TG1F) in concert with c-Jun,
the receptor complex cannot form and TGFb signaling is silenced
[46,47]. Interestingly, the ﬁnding that PML is required for TGFb sig-
naling converges nicely with the observation that APL cell lines
have defects in TGFb signaling [39]. In contrast to the growth sup-
pressive role of physiological levels of TGFb in many cell types, a
wide range of human cancers acquire the capacity to overproduce
TGFb, which drives oncogenic transformation [48]. The contribu-
tion of PML in this deregulation context remains to be deﬁned.
Another role for PML regulation of apoptosis outside the nu-
cleus has been demonstrated in calcium signaling [49] (Fig. 1).
PML in response to stimuli, including endoplasmic reticulum
stress, localizes to mitochondrial-associated membranes (MAMs).
These are specialized signaling domains involved in the induction
of apoptosis through the regulation of Ca2+ transport from the
endoplasmic reticulum to the mitochondria (Fig. 1). The enrich-
ment of cPML at MAMs regulates a large complex involving
PP2A, AKT and IP3R, which ultimately facilitates Ca2+ release from
the endoplasmic reticulum to the mitochondria, and consequently
stimulates apoptosis (Fig. 1) [49].
3. PML isoforms and tumor suppression
The generic use of the name PML implies a single entity; how-
ever, alternative mRNA splicing generates multiple human protein
isoforms. The nomenclature of Jensen et al. was deﬁned more than
a decade ago [50], however considerable confusion regarding PML
isoform identity has arisen in the literature. A comprehensive and
uniﬁed PML isoform numbering was proposed in 2010 by Uniprot
(http://www.uniprot.org/) to systematize the nomenclature (Ta-
ble 1). This classiﬁcation will be adopted in the current review,
with the Jensen classiﬁcation included subsequently in round
brackets.
All known PML isoforms share a common N-terminal domain
and differ in their C-terminus. Most of the protein isoforms, PML-
1 (I) to PML-6 (VI), contain a nuclear localization signal (NLS), for
nuclear homing. PML-7 (VIIb) in contrast lacks a NLS and is there-
fore likely to localize in the cytoplasm. However, alternative splic-
ing of exon 6, which contains the NLS, has been reported for many
isoforms, suggesting the possibility that all PML isoforms can also
exist in a cytoplasmatic form [50]. Notably, PML-1 (I) contains a
nuclear export sequence (NES), which along with the NLS may leadTable 1
Nomenclature of the PML isoforms.
Uniprot nomenclaturea Uniprot accession number Jensen nomenclatureb
PML-1 P29590-1 PML-I
PML-2 P29590-8 PML-II
PML-3 P29590-9 PML-III
PML-4 P29590-5 PML-IV
PML-5 P29590-2 PML-V
PML-6 P29590-4 PML-VI
PML-7 P29590-10 PML-VIIb
PML-8 P29590-3 PML-II
PML-11 P29590-11 PML-Ia
PML-12 P29590-12 PML-IVa
PML-13 P29590-13 PML-IIa
PML-14 P29590-14 PML-VIb
a http://www.uniprot.org/uniprot/P29590.
b Jensen et al. [50].PML-1 (I) to localize in both nucleus and cytoplasm [31]. On this
basis of potential ﬂuidity of location, the exact isoforms contribut-
ing to the cytoplasmic functions of PML remain to be deﬁned (see
Section 2 above). Actually, the speciﬁc function of most PML iso-
forms is unknown, although mounting evidence suggests that indi-
vidual isoforms may play distinct roles (Fig. 1). In mice, according
to GenBank database, there are only two PML RNA isoforms, iso-
forms 1 and 2, but multiple isoforms are suggested at the protein
level [51].
To date, the most studied PML isoform in the context of tumor
suppression mediated through the nucleus is PML-4 (IV), although
it may not be the most abundant (Fig. 1). It was originally de-
scribed as the only PML isoform to be involved in the induction
of premature senescence, through a p53-dependent mechanism
[52]. Since all PML isoforms are able to recruit p53 into the PML-
NBs (at least when over-expressed) [52], the ability of PML-4 (IV)
to stabilize p53 is implied to result from its additional capacity
to also recruit critical partners of p53 modiﬁcation.
PML-4 (IV) can also induce senescence in a p53-independent
manner through a mechanism that depends upon the Rb pathway
[53] (Fig. 1). Further, p53- and/or pRb-independent mechanisms of
growth inhibition have also been demonstrated for PML-4 (IV)
(Fig. 1). PML-4 (IV) positively regulates replicative senescence
through regulation of telomerase activity by sequestering telome-
rase reverse transcriptase (TERT) to PML-NBs, in response to IFNa
treatment [54].
PML-4 (IV) also promotes key apoptotic pathways by regulation
at the transcriptional level (Fig. 1). PML-4 (IV) inhibits transcrip-
tion of the anti-apoptotic protein Survivin [55]. PML-4 (IV) can also
modulate apoptotic signaling pathways by binding to transcription
regulators of apoptotic genes including histone deacetylases
(HDAC) [56], the TNFa-induced NF-jB targets A20 [57] and RelA/
p65 [58], and the transcriptional activator involved in the regula-
tion of cellular responses to growth factors, Nur77 [57]. Further,
PML-4 (IV) interacts with HIPK2 and modulates HIPK2-mediated
enhancement of p53-dependent transcription [59]. Interestingly,
PML-1 (I) has also been shown to regulate apoptosis in a similar
manner due to its capacity to bind Daxx, recruit it to the PML-
NBs, and thereby inhibit Daxx-mediated transcriptional repression
of Fas-mediated apoptosis [60]. Furthermore, PML-4 (IV) was dem-
onstrated to be the only isoform that interacts with Myc, inducing
Myc destabilization and re-activation of Myc-repressed target
genes, including the genes of the tumor suppressive cell cycle
inhibitors: cdkn1a/p21 and cdkn2b/p15 [61]. PML-6 (VI) has been
demonstrated to induce, at the level of transcription, the expres-
sion of proteins implicated in the assembly and exposure of MHC
I on the surface of human lung cancer cells, leading to the restora-
tion of defective antigen presentation and boosting tumor immune
response [62].
Despite the knowledge gained in recent years regarding PML, a
paucity of tools for deﬁnitive characterization of PML isoform pro-
teins limits our knowledge of their functions. A critical ramiﬁcation
of this lack of tools is not only that their normal physiological func-
tions are poorly characterized, but also that any contribution to
pathology remains-ill-deﬁned. Speciﬁcally, when PML levels are
assessed in patient biopsies using pan-PML antibodies, it is only
possible to assess general levels of PML. Also, while immunoblot-
ting allows isoform differentiation on the basis of molecular
weight, it is yet to be deﬁned whether the apparent variation in
levels between isoforms (such as indicated by the greater reactivity
of PML isoforms 1 and 2 (I and II respectively) in healthy cells [63])
reﬂects antibody afﬁnity or actual PML levels. Thus speciﬁc, quan-
tiﬁable reagents to individual PML isoforms are urgently needed to
deﬁne their contribution both to normal function and to malignant
transformation. In addition, the new generation of mouse models
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PML isoform function.
4. Mechanism of PML regulation and therapeutic opportunities
to restore PML
The PML gene rarely undergoes somatic mutations in tumours
other than APL, and its promoter does not undergo epigenetic
silencing [19]. Deregulated RNA splicing is a possible source of iso-
form variation, but has not been extensively studied. Notably, the
literature regarding PML loss rarely distinguishes between iso-
forms, or focuses only on the major isoforms 1 and 2 (I and II
respectively). Aberrant PML post-translational modiﬁcations are
the most characterized mechanism accounting for PML loss in can-
cer. PML is a promising candidate for restoration as an approach to
tumor suppression. Consequently, intense research is currently di-
rected toward delineating its regulation at the post-translational
level. Importantly, treatment of several tumour cell lines lacking
detectable PML, with the proteasome inhibitor MG132, was shown
to induce an increase in PML protein levels and PML-NBs regener-
ation [19]. This provides a rationale for restoring PML expression at
the protein level, as a means to cancer therapy. Molecular path-
ways that promote PML degradation are therefore potential targets
for its restoration. PML degradation is promoted by post-transla-
tional modiﬁcations including ubiquitination, phosphorylation,Grow
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Fig. 2. Mechanisms of PML regulation and potential therapeutic opportunities. PML is ex
SUMOylation (SUMO) and acetylation (Ac), by the enzymes indicated. PML degradation is
PML negative regulators represent potential therapeutic targets to protect PML in the se
some PML modiﬁcations are stabilizing (HIPK2 phosphorylation; acetylation and possibl
the activities of these enzymes for cancer therapy must consider the implications for the
approach of driving PML degradation with either arsenic trioxide or all-trans retinoic ac
broader potential of these drugs are currently under exploration in additional contexts w
and in the context of mutant p53 [86].acetylation, SUMOylation and isomerization (Fig. 2), although
context may inﬂuence the absolute outcomes. These different
modiﬁcations form a complex regulatory network that modulates
the levels of PML and each of these pathways has been implicated
in various types of cancers. Since some of the PML post-transla-
tional modiﬁcations are often required for subsequent ubiquitina-
tion events, targeting PML degradation can potentially be achieved
by using several approaches: targeting the speciﬁc posttransla-
tional modiﬁcation processes (e.g. by introducing a kinase inhibi-
tor), by targeting the speciﬁc PML E3 ubiquitin ligases, or by
using general proteasome inhibitors (e.g. bortezomib marketed
as Velcade, which is currently used in the treatment of several can-
cers [64]).
4.1. PML ubiquitination
Realization that PML fate is signiﬁcantly dictated by protea-
some targeting prompted the quest for facilitating ubiquitin E3 li-
gases [19]. The underlying concept considers that in cancers, PML
degradation occurs at abnormally elevated levels due to excessive
proteasome targeting. Correction of inappropriately high levels of
PML ubiquitination is consequently predicted to be protective.
Blocking the E3 ligases of PML thus proposed as an attractive ap-
proach for cancer therapy. Based on this premise, a number of high
throughput screens have been established in order to identify
inhibitors of E3 ligases [65], with potential for cancer treatment.th suppression
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tensively post-translationally modiﬁed by phosphorylation (P), ubiquitination (Ub),
promoted by ubiquitination, which is frequently primed by phosphorylation. These
ttings where restoration of its tumour suppressive function is desirable. However,
y SUMOylation in some contexts). Appropriate therapeutic intervention to inﬂuence
resident PML populations, be they growth promoting or inhibitory. The less tailored
id (ATRA) has a proven track record against the APL PML-RARa fusion protein. The
here PML promotes survival including CML [11], certain breast cancer subtypes [9]
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ubiquitinates PML, deﬁned its ﬁrst physiological regulator (Fig. 2).
Consistent with this function, in E6AP null mice, PML protein levels
were elevated across multiple organs and cell types. Moreover, pri-
mary bonemarrowderived-cells fromE6AP-deﬁcientmice exhibit a
dramatic increase in PML-NBs number and intensity. These cells
were in turnmore susceptible toDNAdamage-dependent apoptosis,
which correlated with accumulation of PML in the PML-NBs [51].
Critically, we have now linked the E6AP-PML axis to cancer. Specif-
ically, in aMyc-driven B-cell lymphomagenesismousemodel, a par-
tial loss of E6AP restored PML levels and induced cellular senescence
[24]. Most importantly, E6AP levels were elevated and associated
with PML downregulation in more than half of the human B-cell
lymphomas examined [24]. It is now pertinent to test whether an
E6AP inhibitor, suchas the anti-E6APmacrocyclicN-methyl-peptide
[66], will efﬁciently restore PML tumor suppression activity in B-cell
lymphoma (Fig. 2).
PML ubiquitination may also be mediated under normal physi-
ological conditions by docking to kelch-like family member 20
(KLHL20; Fig. 2), which acts as an adapter bridging PML to Cullin3
ubiquitin ligase. This process is potentiated by phosphorylation of
PML, via the kinase CDK and peptidyl–prolyl cis–trans isomerase
Pin1 and (see Section 4.2). In the tumour hypoxia response, HIF-
1a signaling, KLHL20 levels are elevated, and PML is more aggres-
sively targeted for degradation. PML downregulation during pros-
tate cancer progression appears to be promoted by this
mechanism, corresponding with high levels of PML-degradation
mediators [67]. In this context, it would be intriguing to test
whether the Cullin-family E3 ligase inhibitor MLN4924 is capable
of attenuating prostate cancer progression induced by KLHL20-
mediated PML degradation [68].
The E3 ligase, Ubiquitin-like with PHD and RING ﬁnger domains
1 (UHRF1), was also recently identiﬁed to promote ubiquitin-med-
iated degradation of PML (Fig. 2). UHRF1 is up-regulated in a vari-
ety of human malignancies. UHRF1 targeting of PML for
degradation promotes endothelial cell migration and capillary tube
formation [3], both vital to angiogenesis.
The mammalian homogogues of Drosoplia Seven in Absentia
mammalian (SIAH-1/2) Ring E3 ligases ubiquitinate both PML
and the oncogenic PML-RARa and consequently target them for
proteasomal degradation, at least in vitro [69] (Fig. 2). In the very
speciﬁc context of arsenic trioxide treatment, SUMOylation of
either PML-3 (III) (when overexpressed) or PML-RARa is triggered
and precedes ubiquitination by the RING ﬁnger E3 ligase family
member RNF4, which directs their degradation in the proteasome
[70].
4.2. PML phosphorylation
PML phosphorylation appears to be essential for its identiﬁca-
tion as a target for ubiquitination. Emerging data support the con-
cept that a spectrum of kinases is capable of phosphorylating PML,
however each is prompted by distinct stimuli [71]. This suggests
PML regulation is very much context dependent, and that multiple
phosphorylation-dependent mechanisms are likely to dictate its
fate under a variety of physiological conditions and also disease.
In the following sections we will survey that data supporting this
concept.
In response to hypoxia (as mention in Section 4.1), induction of
KLHL20 by HIF-1a results in PML degradation. This process requires
the prior coordinated phosphorylation of PML by CDK1/2, followed
by isomerization of the phosphorylated PML by the isomerase Pin1
(Fig. 2). Importantly, elevated levels of theHIF-1a/KLHL20/Pin1 axis
correlatewith PML loss and it is a signature of high grade aggressive
and chemoresistant human prostate lesions [67].PML regulation through phosphorylation and Pin1 isomeriza-
tion has also been identiﬁed following mitogenic signaling. Expo-
sure to Epithelial Growth Factor (EGF) prompts Extracellular
signal regulated kinase 2 (ERK2) activation and translocation to
the nucleus. In turn, ERK2 mediates PML phosphorylation and sub-
sequent interaction with Pin1, leading to PML degradation by an E3
ligase that remains to be characterized [71] (Fig. 2). An additional
level of regulation is imposed by factors which impact on Pin 1:
where hydrogen peroxide suppresses, and IGF-1 promotes Pin1
activity. Importantly in breast cancer cells, PML negatively regu-
lates Integrin b1 (ITGB1), which inhibits cell migration [72].
Clearly, appropriate regulation of these pathways are critical for
maintaining the tumour suppressive functions of PML in breast
cells.
PML regulation by phosphorylation has also been described
without the observation of associated isomerization. Casein Kinase
2 (CK2) is able to modulate PML protein levels through direct phos-
phorylation of PML, which in turn triggers its ubiquitin-mediated
degradation [23] (Fig. 2). Whether Pin1 is involved in this process
and the identity of the speciﬁc mediating E3 ligase remain to be
determined. Recruitment of CK2 to phosphorylated PML is however
promoted by prior SUMOylation by the E3 SUMO ligase, protein
inhibitor of activated STS-1 (PIAS1) [73]. Importantly, this pathway
may be particularly relevant for the pathogenesis of Non Small Cell
Lung Cancer (NSCLC), where increased CK2 kinase activity in NSCLC
correlates with low PML levels [23]. This data provided a rational for
a therapeutic restoration of PML through CK2 inhibition. Indeed,
applicationof thepharmacological inhibitorof CK2Emodin to estab-
lished lung cancer xenografts, provided the ﬁrst evidence for reacti-
vation of PML tumour suppression in vivo [23].
Another kinase capable of phosphorylating and inhibiting the
tumour suppressive capacity of PML in response to mitogen and
also oncogenic signaling is Big MAP Kinase 1 (BMK1) (Fig. 2). In re-
sponse to stimulation, BMK1 colocalizes with PML in the PML-NBs,
which leads to suppression of PML anti-tumoral actions [74]. Inhi-
bition of BMK1 by a small-molecule inhibitor of its kinase activity,
XMD8-92, blocks tumor cell proliferation in vitro and inhibits tu-
mor growth in vivo in a xenograft model. Activation of BMK1 has
also been demonstrated to interfere with MDM2-PML association,
notably PML-4 (IV), preventing p53 stabilization. Application of the
BMK1 inhibitor, together with the genotoxic drug Doxorubicin is
therefore proposed as a means to protect PML and in turn stabilize
p53 [75].
Importantly however, phosphorylation of PML does not always
lead to its degradation. Phosphorylation-dependent stabilization
occurs after modiﬁcation by the serine/threonine kinase Homeodo-
main-Interacting Protein Kinase (HIPK2) (Fig. 2). As we mentioned
before (see Section 3), PML is required for HIPK2-mediated p53
phosphorylation and apoptosis induction [59]. In response to
DNA damage, HIPK2 also binds to PML, causing PML phosphoryla-
tion and subsequent SUMOylation and stabilization [76].
4.3. PML SUMOylation
Post-translational addition to PML of Small Ubiquitin-like modi-
ﬁer (SUMO) proteins is essential for proper PML-NBs structure and
contributes to normal function. SUMOylation of PML is required
for the recruitment of partners at the PML-NBs, many of which are
SUMOylated themselves [14]. SUMOylation regulates the turnover
and retention of PML in PML-NBs [77] and the integrity of PML-
NBs [12]. SUMOylation of PML is therefore strongly associated with
its capacity to exert tumour suppressive responses, although many
functional aspects remain unclear. Mechanistically, SUMO can
either be non-covalently bound to PML through the SUMO binding
domain or covalently attached by an E1, E2 and E3-ligase enzymatic
cascade [12]. Accumulationof SUMOylationPML is cell cycle-depen-
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Moreover, SUMOylation of PML controls PML stability in response
to extracellular or intracellular stimuli. For example, the DNA dam-
age agent Doxorubicin triggers SUMOylated of PML and its pro-
apoptotic functions [76]. PML-4 (IV) SUMOylation has been shown
to be required for stabilization and full p53 activation at the PML-
NBs [79]. P53 is recruited to PML-NBs where it becomes acetylated
and activated, and participates in the triggering of cellular senes-
cence [52]. TheMelanoma Antigen Gene A2, (MageA2), antagonizes
these functions, through speciﬁc interaction with PML-4 (IV) pre-
venting its SUMOylation and acetylation, and in turn inhibiting
p53-mediated senescence [73] (Fig. 2).
The outcome of PML SUMOylation however appears to be con-
text dependent. While it is essential for PML-NBs formation, it may
also promote PML destruction. As mentioned above, the SUMO E3-
ligase PIAS1 SUMOylates PML and consequently increases associa-
tion with CK2, PML phosphorylation, ubiquitination and degrada-
tion. This pathway is essential for PML degradation in NSCLC cell
lines as well as in arsenic trioxide-mediated degradation of PML-
RARa [80].
4.4. PML acetylation
A potential prerequisite for PML SUMOylation is prior post
translational acetylation. Promotion of PML acetylation by inhibit-
ing Histone Deacetylase (HDAC), using the agent TSA, leads to an
enhanced TSA-induced apoptosis. Pertinently, this acetylation
could be enhanced by p300 acetylase. Histone deacetylase inhibi-
tors (HDACi) are a promising class of targeted anticancer agents,
although little is known about the mechanisms involved in their
effects [81,82]. This observation adds new information about the
therapeutic mechanism of HDACi, since it suggests that enhanced
PML SUMOylation through PML acetylation plays a key role in
TSA-induced apoptosis.
Paradoxically, histone deacetylase 7 (HDAC7) has been shown to
promote PML SUMOylation in response to TNF-a stimulation,
through its SUMO E3-ligase activity in a manner independent of
its HDAC activity. This capacity has also been demonstrated in addi-
tional class IIa HDAC family members [83]. Further, overexpression
of the deacetylase Silent mating type Information Regulation 2
homolog 1 (Sirt1) increases levels of PML protein [84,85] (Fig. 2).
Also in this context, the unexpected explanation for this phenomena
is that Sirt1 is able to increase PML SUMOylation, apparently over-
riding its deacetylation activity. The consequence is enhanced
PML-NB formation [84]. These ﬁndings support a vital role for PML
SUMOylation in promoting its growth suppressive functions and
provoke the question whether the bi-functionality of these HDACs
allow them to act as ﬁne response regulators, either promoting
deacetylation or SUMOylation depending on the context and
stimuli.
5. PML does not always acts as a tumour suppressor:
implication for therapy
In contrast to the usual perception of PML as a classical tumour
suppressor, in recentyears, a growingbodyofworkhas revealed that
PML may provide a selective advantage for tumour cells in certain
settings. In the following sections wewill review the very recent lit-
erature that implicate PML in speciﬁc scenarios to contribute to a
more sinister role in cancer:wheremaintained or even elevated lev-
els of PML correlate with poor clinical outcome.
5.1. PML is required for GOF mut p53
We identiﬁed an unexpected role for PML in the context of
established cells lines harboring mutant p53 [86]. Mutant p53 re-quires PML for cell proliferation since PML knock down in these
cells led to their arrest in G2/M. This contrasts markedly with
the capacity of PML to act as a tumour suppressor during tumour
onset. Intriguingly, in a subset of breast cancers it appears that mu-
tant p53 and elevated PML levels are coincident [9]. Intriguingly
application of arsenic trioxide was observed to degrade mutant
p53 in cancer cells, but whether this was mediated though PML
destruction remains to be identiﬁed [87].
A plausible explanation of the apparent dual and conﬂicting
activities of PMLmay lie in the suggestion that tumour suppression
is the function of the dominant PML isoforms in healthy cells.
However, under the extreme selection pressure exerted during tu-
mor onset, the generation of oncogenes is likely to be advanta-
geous: including mutant p53, and PML isoforms that are growth
supporting. Mutant p53 appears to become addicted to the forms
of PML in these cancer cells (as demonstrated for breast, lung
and intestinal cancer cells lines), which deﬁnes a potential thera-
peutic target [86].
5.2. A metabolic survival role for PML in breast cancer
Elucidation of a growth promoting function for PML has
emerged from breast cancer studies. In contrast to the frequently
low or undetectable PML levels in most breast cancer biopsies
[19], a subset of breast cancer biopsies exhibit higher levels than
normal breast epithelium [9]. In triple negative and basal high tu-
mour grade breast cancers, which are amongst the most untreat-
able cancers subtypes [88], high levels of PML expression
correlates with early tumour recurrence, and deﬁne a signature
of poor prognosis [9].
A capacity for PML to inﬂuence fatty acid oxidation (FAO) pro-
vides a rationale for these increased levels. Mechanistically, PML
promotes the deacetylation and subsequent activation of the tran-
scriptional cofactor PGC1A by recruitment of SIRT1 deacetylase
into PML-NBs. Acetylated PGC1A then triggers the FAO transcrip-
tional program as part of the PPARd complex, which generates high
levels of ATP [9] (Fig. 3). ATP provided by FAO offers a growth
advantage to cancer cells by sustaining enhanced proliferation
and energizes their migration far from the extracellular matrix
[89].
In breast cancer, deregulated PML could therefore provide a
selective advantage by promoting tumoral metabolic reprogram-
ming. Enhanced metabolism would be particularly advantageous
during the metabolically stressful transformation process to meta-
static progression, when normal epithelial glandular structures are
lost and cells detach [9]. This oncogenic property of PML contrasts
dramatically with its better-deﬁned growth suppressive functions
(detailed in previous sections). These ﬁndings provoke the sugges-
tion that targeting both PML and FAO in triple negative breast can-
cer tumors with combination of arsenic trioxide and other PML-
targeted therapiesmay present a novel approach to treat this tumor
subtype (this will be further discussed below). These studies again
raise the fundamental question of how PML can have the capacity to
both suppress and promote growth. The possibility that this conun-
drum is a result of imbalanced expression of PML isoforms, which
may work in concert, or be antagonistic through multimerization
and/or a dominant negative effects, demands exploration.
5.3. A role for PML in the control of stem cell function
A pro-survival function of PML has also been elaborated in
hematopoietic stem cells (HSCs), with important ramiﬁcations for
leukemia (Fig. 3). PML was demonstrated to be indispensible for
quiescence in HSCs [11]. Quiescence is a vital state of inactivity re-
quired to avoid depletion of the HSC compartment, and to allow
the production of multi-potent progenitors in response to environ-
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Fig. 3. The oncogenic side of PML. PML has a pro-survival role in hematopoietic stem cells and in breast cancer cells through activation of PPARc signaling and the fatty acid
oxidation (FAO) transcriptional program. In hematopoietic stem cells (HSC), PML has a dual function of preserving populations in a state of quiescence, which prevents
exhaustion; and also of promoting asymmetric division in cells undergoing division, which maintains the HSC population. This pathway represents a new target for chronic
myeloid leukemia (CML), where inhibition of PML would prompt the cells out of quiescence and shift the balance to promote symmetric cell division. The predicted
consequence would the loss of quiescence and exhaustion of the leukemia-initiating cells (LICs), preventing disease relapse. In breast cancer cells, PML enhances PPARc
signaling by promoting the acetylation of PGC1A (PGC1A-Ac) through recruiting SIRT1 deacetylase into the PML nuclear bodies (PML-NBs). In this context, FAO increases ATP
levels and promotes cell survival and proliferation. Therefore, in CML as well as the subset of triple negative breast cancers where high PML levels correlate with bad
prognosis, targeting PML for degradation may represent a novel therapeutic approach.
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mia-initiating cells (LICs) were also found to be maintained by
PML. These rare cellular pools [92] offer a state of protection during
CML therapy [93] and therefore represent a source of cancer cell
replenishment. Importantly, depletion of PML drives these cells
out of quiescence, their transient ampliﬁcation and subsequent
exhaustion. PML depletion drives both a loss of LICs, and also HSCs.
[11]. Intriguingly, PML was once again found to exert its essential
role in HSC maintenance through the regulation of FAO by PPARd
[94].
Mechanistically, PML controls HSCs asymmetric division
through a pathway which involves PPARd transcriptional activa-
tion of FAO program, analogous to the process described for breast
cancer [9]. In HSCs loss of PML, loss of PPARd or FAO inhibition re-
sults in symmetric division of daughter HSCs and concomitant fail-
ure to produce progenitor cells (Fig. 3). How these metabolic
changes induced by FAO directly control asymmetric cell division
in HSCs remains to be deﬁned. Intriguingly, in HSCs, the PML-
PPARd-FAO axis promotes self-renewal, whereas in the breast can-
cer model, the same metabolic switch allows generation of high
levels of ATP from FAO, promoting cell survival and proliferation
(Fig. 3).
Important ramiﬁcations for therapy are emerging from the ﬁnd-
ings that low levels of PML correlate with better overall survival for
CML patients. Critically, PML downregulation with arsenic trioxide
treatment eradicates LICs through their exhaustion and increases
the efﬁcacy of anti-leukemic therapy, by sensitizing LICs to pro-
apoptotic stimuli [11]. Further, exciting therapeutic perspectives
for hematopoietic malignancies are suggested through direct tar-
geting each of the steps in the PML-PPARd-FAO pathway.Therefore, in addition to arsenic trioxide targeting of PML, it will
be important to explore whether pharmacological intervention to
promote LICs exhaustion could be compounded using PPARd selec-
tive inhibitors like GSK0660 [95] and inhibitors of the mitochon-
drial enzymes responsible for fatty acid catabolism like Etomoxir
[96,97]. As yet it remains to be determined whether PML exerts
the same role in LICs as in HSCs, since the PML-PPARd-FAO path-
way was described in HSCs but not in LICs. In this context, it is
encouraging that, at least in vitro, PML degradation induced by ar-
senic trioxide promotes LICs proliferation and inhibits LICs mainte-
nance in long-term culture [11].
5.4. Therapeutic risks potentially associated with PML activating
therapies
The last decade of PML research has produced fascinating re-
sults which shed light onto the complexity of PML function, open-
ing wide pharmacological perspectives for cancer therapy.
Critically, while PML acts as a tumor suppressor in most of the set-
tings evaluated so far, in a subset of cancers (over and above its
capacity in APL), PML acts as a pro-survival factor. These ﬁndings
challenge the notion that PML serves as a potent pro-apoptotic fac-
tor in all conditions. The ramiﬁcation of this realization is that
careful analysis of the nature of PML in individual cancers should
be appraised in order to design appropriate therapeutic regimens.
This dual role of PML in tumorigenesis has important implica-
tions for therapeutic interventions. In this context, therapies direc-
ted to protect PML (reviewed in the Section 4) should be cautioned
against, in the settings where PML provides a selective advantage:
including CML and a subset of breast cancer. For the treatment of
2660 C. Gamell et al. / FEBS Letters 588 (2014) 2653–2662cancer types where PML plays an oncogenic role, the use of PML
inhibitors could represent a new therapeutic approach of remark-
able application. Oncogenic PML could be pharmacologically tar-
geted using all-trans retinoic acid (ATRA) or arsenic trioxide, two
well-tolerated drugs that are highly effective in promoting PML
degradation and have been extensively used in the treatment of
acute promyelocytic leukemia [98–101]. Downregulation of PML
could also be achieved by enhancing the levels or activity of
RNF4, an E3 ubiquitin ligase that is essential for arsenic trioxide-in-
duced PML degradation [70]. It will be important to preclinically
evaluate the ramiﬁcations of all these approaches on healthy cell
populations before advancing to clinical trials.
More precise deﬁnition of the function of PML isoforms as well
as their interplay and function in particular cellular compartments
is critical for designing appropriate cancer therapies directed to-
ward PML. Further, additional studies are required to avoid the po-
tential risk of therapeutically protecting PML isoforms with
oncogenic character, or targeting for degradation the isoforms with
tumor suppressor functions. Importantly, where PML expression
correlates with tumor grade and prognosis [9,19], the assessment
of PML status, and ideally the levels of the speciﬁc PML isoforms,
could be used as a prognostic marker. Immunohistochemical
assessment of PML total protein status has been successfully estab-
lished as a diagnostic approach in APL [102]. However, APL is de-
ﬁned by an unique PML fusion protein and generation of speciﬁc
antibodies to detect PML speciﬁc isoforms will be essential for
application to additional cancer types.
In summary, the emerging concept of the dual role of PML in
tumorigenesis represents a change in paradigm in cancer research
and asks for the design of new therapeutic approaches.
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